Does Regence Cover Prolia?

Regence Prolia Coverage: The Short Answer

Regence BlueCross BlueShield covers Prolia (denosumab) as a medical benefit for members who meet specific clinical criteria. The drug is classified as a physician-administered injectable, which means it is billed under your medical benefit rather than through a retail pharmacy. This distinction matters because it determines your cost-sharing structure.

Which Regence Plans Include Prolia

Most Regence commercial PPO, HMO, and EPO plans include Prolia coverage when prior authorization criteria are satisfied. Regence Medicare Advantage plans also cover Prolia under Medicare Part B guidelines, which classify denosumab as a Part B drug when administered in a physician's office [1]. Individual and family plans purchased through state exchanges (Oregon, Washington, Utah, Idaho) follow the same medical policy but may carry different cost-sharing tiers.

The Medical Benefit vs. Pharmacy Benefit Distinction

Because Prolia is given as a subcutaneous injection every six months in a clinical setting, Regence processes claims through the medical benefit. This means your copay is calculated as a percentage of the allowed amount (coinsurance) rather than a flat pharmacy copay. Members on high-deductible plans should expect to pay the full negotiated rate until their deductible is met. For a drug with a wholesale acquisition cost near $1,991 per dose, that can be a significant upfront expense [2].

Prior Authorization Requirements

Regence requires prior authorization for Prolia on all plan types. Your prescribing physician or their office staff must submit documentation proving you meet the insurer's medical necessity criteria before your first injection. Without this approval, the claim will be denied.

What Regence Requires for Approval

The standard Regence prior authorization criteria for Prolia include a confirmed diagnosis of osteoporosis based on a DXA scan showing a T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip, or a T-score between -1.0 and -2.5 with a FRAX 10-year major osteoporotic fracture probability of 20% or greater [3]. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines support these thresholds as appropriate treatment triggers for pharmacologic intervention [4].

Regence also accepts prior fragility fracture (hip or vertebral) as an independent qualifying criterion, regardless of DXA score. This aligns with the position of the Endocrine Society's 2019 clinical practice guideline, which states that "postmenopausal women with a hip or vertebral fracture should be treated with pharmacologic therapy to reduce fracture risk" [5].

Step Therapy: The Bisphosphonate-First Rule

Most Regence plans enforce step therapy for Prolia. You must demonstrate a trial and failure of, or contraindication to, at least one oral bisphosphonate before Regence will authorize denosumab. Alendronate (generic Fosamax) is the most commonly required first-line agent [6].

Acceptable reasons to bypass step therapy include documented gastrointestinal intolerance to oral bisphosphonates, esophageal disorders such as Barrett's esophagus or achalasia, inability to remain upright for 30 minutes after dosing, renal impairment with an eGFR below 30 to 35 mL/min (bisphosphonates are contraindicated in severe renal impairment), and continued bone loss or fracture while on bisphosphonate therapy [7].

Your physician should document these reasons explicitly in the prior authorization submission. Vague statements like "patient prefers injectable therapy" are consistently denied.

What You Will Pay Out of Pocket

Your actual cost for Prolia under Regence depends on your plan type, deductible status, and whether you have met your out-of-pocket maximum for the year.

Regence Commercial Plan Costs

On a typical Regence commercial PPO plan with a $2,000 deductible, you will pay the full negotiated rate for Prolia until your deductible is met, then a coinsurance percentage (commonly 20%) of the allowed amount. If the negotiated rate is $1,600 and your coinsurance is 20%, you would pay $320 per injection after deductible. Many members report effective per-injection costs between $30 and $150 once deductibles are satisfied, depending on plan design.

Regence Medicare Advantage Costs

For Regence Medicare Advantage members, Prolia is covered under Part B. After meeting the 2026 Part B deductible of $257, you typically pay 20% coinsurance. If the Medicare-allowed amount for a Prolia injection plus administration is approximately $1,800, your coinsurance would be roughly $360 per injection [8]. Supplemental coverage or Medigap policies can reduce this further.

Reducing Your Cost

Amgen's Prolia patient assistance program offers eligible commercially insured patients a copay card that can reduce out-of-pocket costs to as little as $0, with a maximum annual benefit. This card does not apply to government-insured patients (Medicare, Medicaid, Tricare). For Medicare patients, Amgen's Safety Net Foundation provides free Prolia to those who meet income eligibility requirements [9].

Clinical Evidence Behind Prolia Coverage Decisions

Insurance coverage criteria for Prolia are grounded in clinical trial data demonstrating fracture risk reduction. Understanding this evidence can help you and your physician build a stronger prior authorization case.

The FREEDOM Trial

The key FREEDOM trial (N=7,868) randomized postmenopausal women with osteoporosis to denosumab 60 mg or placebo every six months for three years. Denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared to placebo [10]. These results formed the basis of the FDA's 2010 approval and remain the foundation of most payer coverage policies.

Long-Term Extension Data

The FREEDOM Extension study followed participants for up to 10 years of continuous denosumab therapy. Over this period, fracture rates remained low, with annual vertebral fracture incidence of 0.90% to 1.86% during years 4 through 10 [11]. Bone mineral density at the lumbar spine increased continuously, reaching gains of 21.7% over the full 10-year treatment period. The Endocrine Society has noted that "denosumab is one of few osteoporosis therapies with data supporting efficacy beyond 5 years" [5].

The Discontinuation Problem

One clinical consideration that affects coverage decisions is the rebound vertebral fracture risk after stopping Prolia. A 2017 analysis published in the Journal of Bone and Mineral Research found that patients who discontinued denosumab experienced rapid bone loss and an increased rate of multiple vertebral fractures, with the risk concentrated in the 12 to 18 months following the last dose [12]. This has led professional societies, including AACE, to recommend that patients transitioning off denosumab should receive a bisphosphonate to preserve bone density gains [4]. Regence may factor this into long-term coverage decisions.

How to Get Regence to Approve Prolia

If your physician recommends Prolia, there are specific steps that increase the probability of first-pass approval.

Build the Clinical Case Before Submitting

Ensure your medical record includes a recent DXA scan (within the past 24 months), a documented FRAX score calculation if your T-score is in the osteopenia range, records of any prior bisphosphonate therapy (dates, duration, reason for discontinuation), and documentation of any fracture history. The National Osteoporosis Foundation recommends pharmacologic treatment when T-scores are at or below -2.5, or when FRAX 10-year hip fracture probability reaches 3% or major osteoporotic fracture probability reaches 20% [13].

Submit Complete Documentation the First Time

Incomplete submissions are the most common reason for Prolia prior authorization delays. Your physician's office should include the DXA report, relevant lab results (serum calcium, vitamin D, renal function), a medication history showing prior bisphosphonate use, and a letter of medical necessity if the request falls outside standard criteria.

What to Do If Regence Denies Coverage

If Regence denies your Prolia prior authorization, you have the right to appeal. The first level is an internal appeal directly to Regence, which must be decided within 30 days for non-urgent requests. Include any new clinical information that was not in the original submission.

If the internal appeal is denied, you can request an external review through your state's insurance division (Oregon Division of Financial Regulation, Washington Office of the Insurance Commissioner, or the equivalent agency in Utah or Idaho). External reviews are conducted by independent physicians and are binding on the insurer.

A peer-to-peer review, where your physician speaks directly with the Regence medical director, is often the most effective route. Physicians who can articulate specific clinical reasons for Prolia over alternatives, such as renal impairment precluding bisphosphonate use, report higher approval rates.

Alternatives If Prolia Is Not Covered

If Regence denies Prolia coverage or the out-of-pocket cost remains prohibitive, several alternative osteoporosis treatments may be available under your plan.

Oral Bisphosphonates

Generic alendronate costs $4 to $15 per month and is covered on virtually all Regence formularies without prior authorization. Risedronate (generic Actonel) is similarly priced. Both have strong fracture reduction evidence. The Fracture Intervention Trial (FIT) showed alendronate reduced vertebral fractures by 47% and hip fractures by 51% in women with existing vertebral fractures over three years [14].

Intravenous Zoledronic Acid

Zoledronic acid (Reclast) is a once-yearly IV bisphosphonate that Regence covers as a medical benefit. The HORIZON Key Fracture Trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and 41% reduction in hip fractures over three years [15]. For patients who cannot tolerate oral bisphosphonates but do not have severe renal impairment, zoledronic acid may be approved without the step therapy required for Prolia.

Romosozumab

For very high-risk patients (those with T-scores below -3.0 or multiple fractures), romosozumab (Evenity) may be an option. The ARCH trial showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared to alendronate alone [16]. Regence covers romosozumab with prior authorization, but criteria are stricter than for Prolia, typically requiring very high fracture risk or failure of other agents.

Special Populations and Coverage Considerations

Regence's Prolia coverage extends beyond postmenopausal osteoporosis, though criteria vary.

Glucocorticoid-Induced Osteoporosis

Patients receiving chronic glucocorticoid therapy (prednisone 7.5 mg/day or higher for 3 months or more) who develop osteoporosis may qualify for Prolia coverage. The ACR 2022 guideline for glucocorticoid-induced osteoporosis recommends denosumab as a conditional option for patients at moderate-to-high fracture risk [17].

Men With Osteoporosis

Prolia is FDA-approved for men with osteoporosis at high fracture risk. The ADAMO trial (N=242) demonstrated that denosumab increased lumbar spine BMD by 5.7% in men with low bone mass over 12 months [18]. Regence applies the same prior authorization criteria for men as for postmenopausal women.

Cancer Treatment-Related Bone Loss

Regence covers Prolia for bone loss in men receiving androgen deprivation therapy for prostate cancer and women receiving aromatase inhibitor therapy for breast cancer, consistent with the FDA-approved indications. The prior authorization process for these indications may differ from the osteoporosis pathway, and oncology teams typically handle the submission.

Timing Your Prolia Injection With Coverage

Because Prolia must be given every six months (plus or minus one month, according to the prescribing information), timing your injections relative to your plan year can affect costs. If your deductible resets on January 1, scheduling both annual injections in the same calendar year means you only need to meet one deductible. An injection in November and the next in May splits costs across two deductible periods.

Discuss injection timing with both your physician and your Regence member services representative. Prior authorizations for Prolia are typically valid for 12 months, covering two injection cycles per approval period.